Riotech Pharmaceuticals Ltd
Riotech is an early stage biotherapeutics company, established to exploit the work in Viral Hepatitis undertaken at Imperial College, London and at Oxford University through the Wellcome Trust Centre for Human Genetics. At the core of the company is the highly developed understanding of hepatitis viral pathogenesis, immune system response and identification and understanding of the genetics and host pathway management of chronic infection. Riotech has commercial out-licence lead candidates in interferon and vaccines medicines, and will continue to focus on its HCV treatment development programme.
Contact
Dr Mark Thursz
Chief Scientific Officer
Riotech Pharmaceuticals Ltd
E m.thursz@riotechpharma.com